XTENT

XTENT Announces Plan for NASDAQ Delisting and Filing of Certificate of Dissolution

...on and NASDAQ a Form 25 relating to the delisting of XTENT's common stock. xtent expects that trading in its common stock will be permanently suspended by N...er records and discontinue recording transfers of the common stock. xtent also announced today the filing of its Certificate of Dissolution with the ...

XTENT, Inc. Announces That It Has Postponed the Special Meeting of Its Stockholders

...obtain adequate financing, the need for domestic and foreign regulatory approval and approval by the board and stockholders of each party. About xtent XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent ("DES") systems for...

XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration

...f XTENT, Inc. "I want to recognize each and every xtent employee, and especially Dr. Philippe Marco, our V...n of the Company subject to stockholder approval. xtent intends to hold a special meeting of stockholders ...complete liquidation and dissolution. About xtent XTENT, Inc. is a medical device company focused...

XTENT, Inc. Announces Approval of Plan of Liquidation and Dissolution by Board of Directors and Filing of Proxy Materials With the SEC

...or investment decision with respect to the Plan of Dissolution. About xtent XTENT, Inc. is a medical device company focused on developing and commer... no reasonable strategic alternatives to the dissolution and liquidation of xtent become available, and that distributions to stockholders may take several y...

XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System

...imus A9TM and the biodegradable drug carrier, PLA. xtent has completed four clinical trials with follow-up ...proved for sale in the United States. About xtent XTENT, Inc. is a medical device company focuse...ne cause of death in the United States and Europe. xtent Custom NX DES Systems are designed to enable the t...

XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress

...er of 2007. For the year ended December 31, 2008, xtent had a net loss of $41.1 million, compared to $38.8...e same period last year. As of December 31, 2008, xtent had cash, cash equivalents and short-term investme...for the same period in 2007. On January 23, xtent announced an initiative to reduce headcount by eli...

XTENT Announces Third Quarter 2008 Financial Results

...or the third quarter of 2007. For the nine months ended September 30, 2008, xtent had a net loss of $34.0 million, compared to $26.9 million for the same per...on compared to $7.9 million for the same period in 2007. On July 9, 2008, xtent announced the implementation of cost reduction initiatives through a workfo...

XTENT Announces Second Quarter 2008 Financial Results and Business Progress

...r of 2007. For the six months ended June 30, 2008, xtent had a net loss of $25.3 million, compared to $17.4...or the same period last year. As of June 30, 2008, xtent had cash, cash equivalents and short-term investme...on for the same period in 2007. On July 9, 2008, xtent announced the implementation of cost reduction ini...

XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors

...r Ventures, a founding venture capital investor in xtent and a board member since 2002, will leave his boar...sume their duties. "Robin's support and service to xtent since our first days as a company have been invalu...ts, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any fo...

XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention

...C's website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they wer...

XTENT in Medical Technology

XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week

...C's website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they wer...

XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention

...C's website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they wer...

XTENT Announces European Regulatory Update

...C's website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they wer...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

...ity. CUSTOM III Webcast and Slide Presentation As previously announced, xtent will host a teleconference and slide presentation to review the CUSTOM III ... forward-looking statements, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any forward-looking statements ...

XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week

...sion on the six best papers from EuroIntervention. xtent is also sponsoring an evening symposium on customi...ing at booth E11 in the main hall. Schedule of xtent Events for EuroPCR Tuesday, May 13, 2008, 3:30-6:...ts, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any fo...

XTENT Announces First Quarter 2008 Financial Results

... for the first quarter of 2007. At March 31, 2008, xtent had cash, cash equivalents and short-term investme... customizable drug-eluting stents. Schedule of xtent Events for EuroPCR Tuesday, May 13, 2008, 3:30-6...ts, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any fo...

XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System

...t and Slide Presentation As previously announced, xtent will host a teleconference and slide presentation ...Web site at http://investor.xtentinc.com . About xtent XTENT, Inc. is a medical device company focused o...ts, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any fo...

XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007

...ober 21 Event: The Drug-Eluting Stent Summit: The xtent CUSTOM Biolimus-Eluting Modular Stent Program (Fo...nd Teleconference on CUSTOM I and CUSTOM II Data xtent will host a webcast and teleconference call to rev...tentinc.com Time/Location: 7:00 a.m. EDT About xtent XTENT, Inc. is a medical device company focused o...

XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting

...ve early clinical results, with two MACE events in xtent CUSTOM NX treated patients, zero restenosis and ze... patients at up to 15 European centers is ongoing. xtent expects to submit an IDE application to the FDA wi...2007. CUSTOM II webcast and slide presentation xtent will host a webcast, slide presentation and telebr...

XTENT in Biological Technology

XTENT to Retain Investment Bank to Pursue Strategic Alternatives

...ing or terms of any such transaction. About xtent XTENT, Inc. is a medical device company focuse...IMPLEMENT A STRATEGIC ALTERNATIVE, THE DECISION BY xtent TO EXPLORE ONE OR MORE STRATEGIC ALTERNATIVES, WHE...ts, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any fo...

Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years

...C's website at http://www.sec.gov . Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. xtent undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they wer...